Executive Chairman
President
VP of Strategy
VP of Finance
VP of Quality & Regulatory Affairs
VP of Project Management Organization
VP of Operations
AVP of Business Development, Drug Substance
AVP of Human Resources
AVP of Innovation & Process Strategy
General Manager
The diverse background of our analytical team gives Nitto Avecia Pharma Services an in-depth understanding of all facets of the drug development process. Their expertise translates into accurate chemical and microbiological results you can rely on to ensure the successful manufacturing of your product.
President
Seiji Fujioka, President of Nitto Avecia, Inc.’s Human Life Science division since 2018, has steered the organization through a period of remarkable growth. He concurrently serves as the Corporate Senior Vice President of Nitto’s Medical Division, overseeing numerous projects in the medical device and pharmaceutical sectors. Seiji has been an integral part of Nitto since 1985, embodying the company’s core value, “Innovation for Customers.” He holds a Bachelor’s degree from Doshisha University.
VP of Finance
Chun Ren, Nitto Avecia’s VP of Finance. Chun brings over two decades of technology management and finance leadership experience across the global biotech, pharmaceutical, medical device, and CDMO industries. Chun has a proven track record in business partnership, strategic planning, driving profitability, fostering business growth, and building robust finance organizations and processes.
She possesses extensive expertise in financial operations, including accounting, financial planning and analysis, treasury management, internal controls, and SOX compliance. Chun has played a pivotal role in supporting large-scale capital investment projects, including CDMO expansions and mergers and acquisitions.
Chun holds an MBA in Finance from the UCLA Anderson School of Management, a Master of Science degree in Chemistry from the University of California, Riverside, and dual Bachelor of Science degrees in Chemistry and Intellectual Property Law from Peking University.
President
Tammy Cooper, President, has been with Nitto Avecia since 2005 and has played a vital role in increasing the business growth throughout her tenure. Prior to taking on the role of President in 2024, Tammy was the Vice President of Business Development since 2017. Tammy is unwavering in her commitment to build a strong foundation based on innovation, sustainability, and customer centricity to maintain our success as one of the top CDMOs in the oligo market. With over two decades in the pharmaceutical industry, Tammy holds a Bachelor’s degree in Chemistry from the University of Prince Edward Island.
General Manager, California
Atef Khezri, General Manager, brings with him more than 18 years of Operations leadership experience within the global life sciences companies. His expertise encompasses various fields including vaccine manufacturing, cell and gene therapy, biologics CDMOs, and medical devices. He has manufacturing experience in both clinical and commercial scale. Atef is driven by his passion for continuous improvement, adept problem-solving skills, unwavering commitment to quality and compliance, and dedication to operational excellence. He holds a Bachelor’s degree in Pharmaceutical Sciences from the University of Toledo, College of Pharmacy.
VP of Human Resource
Emily Pullen,Vice President of Nitto Avecia and Nitto Avecia Pharma Services. Emily is a seasoned professional in the field of Human Resources, boasting a J.D. from the University of Pittsburgh School of Law. She has honed her skills as an HR attorney and culture and compliance consultant with extensive HR executive leadership experience. With over 20 years of international and US-based HR experience, Emily brings a wealth of strategic HR leadership experience in numerous industries including medical technology.
VP of Research and Development
Prasad Panzade, Ph.D. brings over 25 years of experience in the multidimensional chemical industries, encompassing both pharmaceutical and biopharmaceutical sectors. Dr. Panzade holds a Ph.D. in Pharmaceutical Sciences, specializing in pharmaceutical product development, as well as analytical sciences and technology.
Throughout his career, Dr. Panzade has been an active member of several professional organizations, including AAPS, IPA, and SPDS. He is also a dedicated mentor, committed to cultivating the next generation of leaders in the industry. Before joining us, Prasad served as the Head of Analytical Sciences and Laboratory Operations at Catalent, Inc.
Prasad’s extensive expertise and leadership will be vital in advancing our research and development objectives, driving innovation, and enhancing our capabilities in product development and analytical sciences.
VP of Business Development & Project Management
Craig Dobbs, Vice President of Business Development & Project Management is responsible for Avecia’s commercial activities including sales, marketing, business development, and project management. Craig brings over 30 years of technical and client experience in the synthetic biomolecule market having initially trained as a nucleic acid, oligo, and peptide chemist at the Rockefeller University and the University of California Irvine before initiating his commercial career. Craig’s leadership and expertise will be instrumental in achieving our business objectives and fostering a culture of excellence within the organization.
General Manager, California
Nathan Poole is the General Manager at the Irvine CA Pharma facility and a recent addition to the Nitto Avecia Team since May 2021. He is responsible for the operational management of the site to ensure the continued development and execution of a world class contract manufacturing organization and analytical service provider. Nathan has over 18 years of experience in the pharmaceutical and combination device industry from which the vast majority has been within the CDMO space. Nathan has broad hands-on experience throughout operations, supply chain, and an extended history in operating through multiple global regulatory markets. Nathan holds a Bachelor degree in Biology from the University of New Mexico.
VP of Quality & Regulatory Affairs
Dr. Qu brings over 20 years of technology development and quality management expertise gained from leading roles in several multinational pharmaceutical companies. Her extensive experience spans Pharmaceutical Quality Systems and Quality Risk Management, encompassing all GxP activities to uphold regulatory compliance, ensure product quality, and protect patient safety. Susan is passionate about cultivating a culture of quality throughout organizations through a holistic approach, collaborating closely with all functional teams. Before joining Nitto Avecia, Dr. Qu held progressive quality leadership positions at Abio-X Holdings, WuXi Biologics, Thermo Fisher Scientific, Takeda Pharmaceuticals, and Genzyme Sanofi.
Dr. Qu obtained her Ph.D. in Chemistry from Emory University, and her MBA from Babson College.
Vice President
Masaki Hayashi, Vice President of Nitto Avecia and Nitto Avecia Pharma Services, has more than 20 years of experience in the chemical field at Nitto Denko Corporation. He has held key roles in the R&D, Intellectual Property, Oligonucleotide Drug Discovery, and Corporate Planning Divisions of Nitto Denko Corporation, primarily responsible for strategic planning, business development, and alliances. Most recently, since 2022, he has been responsible for strategic planning for the Human Life Solutions Sector.
Hayashi holds a Master’s degree in Materials Science and Engineering from the University of Hyogo.
Executive Chairman
Yoshihiko Terada, Executive Chairman, has been with Nitto Avecia since 2022 and has served as Vice President and Director of the Medical Division at Nitto Denko Corporation since 2015. Before joining Nitto Denko Corporation, Yoshi had 10 years of experience in the pharmaceutical industry and consulting firms, respectively. He is committed to contributing to patients and the oligonucleotide market through Nitto Avecia’s excellent capabilities, along with Nitto Denko Corporation’s brand and core technologies. Yoshi holds a Bachelor’s degree in Economics from Doshisha University.
VP of Operations
Paul Van Norman, VP of Operations at Nitto Avecia, continues to lead Milford’s manufacturing, facilities, business planning, and shipping teams. Since joining the company in 1995, Paul has dedicated his career to oligonucleotide manufacturing, witnessing Avecia’s evolution from a CMO producing grams of material to an industry leader handling products weighing hundreds of kilograms. He is deeply passionate about the continuous growth of oligonucleotides as a primary therapeutic motif. Paul holds a Bachelor’s degree in Natural Sciences from Worcester State University, along with certificates in Biotechnology Manufacturing, Continuous Process Improvement, and Management and Leadership.
AVP of Business Development, Drug Substance
Keri Dufault, Associate Vice President at Nitto Avecia, leads the company’s business development and marketing efforts. With 20 years of experience in the oligonucleotide market, Keri plays a key role in fostering strategic partnerships and driving growth initiatives.
She began her career at Avecia in 2006 as a Process Chemist and has since held a variety of roles across manufacturing and business development. Since 2015, she has advanced through the business development team, progressing from Proposal Writer to her current executive leadership position.
Keri’s strong technical foundation, combined with her expertise in oligonucleotide development, client engagement, and strategic planning, supports Nitto Avecia’s mission to advance therapeutic innovation. She holds a Bachelor’s degree in Natural Science from Saint Anselm College.
AVP of Human Resources
Michael Schick, Associate Vice President of HR. Michael is a seasoned human resources leader with broad experience in building and strengthening HR functions that drive organizational effectiveness and people-centric culture. He has over 20 years of experience in HR for life sciences organizations — with a focus on performance, leadership development, and key talent retention.
Michael earned a Bachelor’s degree from the University of Wisconsin in Psychology & Management and a Master’s degree from the University of Minnesota, Carlson School of Management.
VP, Project Management Organization
Justine Camire, PMP, Vice President of the Project Management Organization (PMO). Justine has 20 years of experience in various leadership roles across the pharmaceutical and biotech industries. She brings deep experience in operational excellence, alliance management, project management, governance, portfolio prioritization, CMC strategy and business operations. Prior to joining Nitto Avecia, Justine held progressive leadership positions at several well-known therapeutics, biotech, biopharma, and specialty pharma organizations.
Justine earned a Bachelor’s degree in biology from Salve Regina University and is a member of the Project Management Institute (PMI).
AVP, Innovation & Process Strategy
Huihe (Julia) Zhu, PhD, Associate Vice President, Innovation & Process Strategy is an expert in oligonucleotide development. She provides both technical and strategic leadership for Process Development, Technology and Innovation, and oversees the Small-scale Oligo Unit (SSOU) for Nitto Avecia.
Julia has a PhD in Organic Chemistry from Northwestern University. She has a strong background in design, development, and pre‑clinical manufacturing of oligonucleotide compounds. She plays a key leadership role in driving safe, compliant, and efficient operations that support our long‑term innovation and modernization.
Executive Chairman
Fumiteru Asai is Executive Chairman at Nitto Avecia. He also serves as Director of the Medical Division at Nitto Denko Corporation, a role he has held since 2026.
He brings extensive leadership experience from Nitto Denko Corporation, where he has held key roles including responsibility for semiconductor-related materials businesses and leadership of the Corporate Strategy function. Leveraging Nitto Denko Avecia’s long-established manufacturing technologies and capabilities in oligonucleotide therapeutics, he is committed to supporting the growth of the oligonucleotide market and contributing to better outcomes for patients.
Asai holds a Bachelor’s degree in Electronic Engineering from Yamagata University in Japan.
General Manager
William Stowell is General Manager and Chief Financial Officer of Nitto Avecia Pharma Services. He leads site operations with a focus on operational stability, quality, and customer delivery.
Bill has brought strong leadership and financial oversight across performance, contracts, and risk management to Nitto Avecia Pharma Services for over ten years. He is a CPA with over 40 years of experience in accounting and finance with a focus on biopharmaceutical, manufacturing, advertising, high tech, and international security — including with PriceWaterhouseCoopers.
He has a bachelor’s degree in accounting from USC Marshall School of Business.
10 Vanderbilt Avenue
Irvine, CA 92618
Tel: (949)-951-4425
6 Vanderbilt Avenue
Irvine, CA 92618
Meet us at one of these conferences:
May 11-14, 2026
TIDES USA
Boston, MA
May 11-15, 2026
ASGCT Annual Meeting
Boston, MA
